All In Biotech

Investigational drug · Phase 2

ACP-211

Not approved by FDA. In 1 industry-sponsored Phase 2 or 3 trial that is active or finished in the last two years, most often for Major Depressive Disorder (MDD), Depressive Disorder, Treatment-Resistant.

Phase 2

Last checked: Nov 19, 2026Latest source record: Nov 5, 2026 (newest trial update)Source: ClinicalTrials.govMethods & limitations

Highest phase

Phase 2

Industry-sponsored trials

Phase 2 and 3 trials

1

1 still active

All registered trials

1

Any phase or sponsor naming "ACP-211"

First trial start

2025

Nov 14, 2025

Sponsors

Lead sponsors of its Phase 2 and 3 trials.

All registered trials by phase

Every ClinicalTrials.gov drug study naming "ACP-211", any sponsor or status.

Conditions studied

As listed on its trial records.

  • Major Depressive Disorder (MDD)
  • Depressive Disorder, Treatment-Resistant

Approved drugs for the same conditions: Depression (major depressive disorder) · Psychiatry

Largest trials

Live from ClinicalTrials.gov: studies naming "ACP-211" as an intervention, largest first.

All trials

Newest research

PubMed records naming it or its code names, newest first.

All 0 on PubMed

No PubMed records name it yet, which is common for early code-named drugs.

Also in development for Major Depressive Disorder (MDD)

  • KH607Phase 34 trials

    Chengdu Kanghong Pharmaceutical Group Co., Ltd. · Major Depressive Disorder (MDD), Postpartum Depressive Disorder

  • CYB003Phase 33 trials

    Cybin IRL Limited · Major Depressive Disorder, Major Depressive Disorder (MDD), Depression in Adults

  • CSPC Ouyi Pharmaceutical Co., Ltd. · Major Depressive Disorder (MDD)

  • DT-101Phase 22 trials

    Draig Therapeutics Ltd · Major Depressive Disorder (MDD)

  • SPT-300LYT-300, GlyphAlloPhase 22 trials

    Seaport Therapeutics · Major Depressive Disorder (MDD), Major Depressive Disorder With Anxious Distress

  • NH102Phase 21 trial

    Jiangsu Nhwa Pharmaceutical Co., Ltd. · Major Depressive Disorder (MDD)

  • SPN-821Phase 21 trial

    Supernus Pharmaceuticals, Inc. · Major Depressive Disorder (MDD)

Names are merged from how sponsors list this drug on ClinicalTrials.gov, so an alias can occasionally belong to a related compound. Development status changes faster than registry records do.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.